Biodesix, Inc. (NASDAQ:BDSX – Get Free Report) CEO Scott Hutton sold 29,708 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $1.66, for a total value of $49,315.28. Following the completion of the transaction, the chief executive officer now owns 465,011 shares in the company, valued at approximately $771,918.26. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Scott Hutton also recently made the following trade(s):
- On Friday, February 9th, Scott Hutton sold 34,682 shares of Biodesix stock. The shares were sold at an average price of $1.92, for a total value of $66,589.44.
Biodesix Price Performance
Shares of NASDAQ BDSX opened at $1.65 on Tuesday. The company has a market cap of $149.29 million, a PE ratio of -1.83 and a beta of 1.24. The stock has a fifty day moving average price of $1.84 and a 200 day moving average price of $1.63. Biodesix, Inc. has a 1-year low of $1.03 and a 1-year high of $2.45.
Wall Street Analysts Forecast Growth
Hedge Funds Weigh In On Biodesix
Several hedge funds have recently bought and sold shares of BDSX. Charles Schwab Investment Management Inc. acquired a new stake in Biodesix in the first quarter valued at $38,000. Tower Research Capital LLC TRC purchased a new stake in shares of Biodesix in the 3rd quarter worth about $52,000. CI Private Wealth LLC purchased a new stake in shares of Biodesix in the 4th quarter worth about $57,000. HRT Financial LP acquired a new stake in Biodesix in the 1st quarter valued at about $61,000. Finally, Susquehanna International Group LLP purchased a new position in Biodesix during the 1st quarter valued at about $68,000. 21.24% of the stock is owned by hedge funds and other institutional investors.
Biodesix Company Profile
Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
- Five stocks we like better than Biodesix
- Investing in Construction Stocks
- 3 attractive stocks that insiders are buying
- How to Evaluate a Stock Before Buying
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.